2,288
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate

ORCID Icon, ORCID Icon, , , , ORCID Icon, , , ORCID Icon, ORCID Icon, , , , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 71-86 | Received 07 Dec 2022, Accepted 30 Jan 2023, Published online: 15 Mar 2023

References

  • Atiq F, Saes JL, Punt MC, et al. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine. 2021;32:100726.
  • Kulkarni R. Improving care and treatment options for women and girls with bleeding disorders. Eur J Haematol. 2015;95(Suppl 81):2–10.
  • National Institutes for Health. Consideration of sex as a biological variable in NIH-funded research (additional guidance for NOT-OD-15-102) [cited 2022 May 3]. Available from: https://orwh.od.nih.gov/sites/orwh/files/docs/NOT-OD-15-102%20Guidance.pdf.
  • James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280–300.
  • Abe K, Dupervil B, O’Brien SH, et al. Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease. Am J Hematol. 2020;95(1):10–17
  • James AH. Heavy menstrual bleeding: work-up and management. Hematology Am Soc Hematol Educ Program. 2016;2016(1):236–242.
  • Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351(9101):485–489
  • Munro MG, Critchley HOD, Fraser IS. Figo Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408.
  • Haamid F, Sass AE, Dietrich JE. Heavy menstrual bleeding in adolescents. J Pediatr Adolesc Gynecol. 2017;30(3):335–340.
  • Rauch A, Valentino LA, Mills K, et al. Big picture initiatives in bleeding disorders. Haemophilia. 2022;28(Suppl 4):53–60
  • Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194.
  • Cohen BJ, Gibor Y. Anemia and menstrual blood loss. Obstet Gynecol Surv. 1980;35(10):597–618.
  • Smith C, Teng F, Branch E, et al. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. Obstet Gynecol. 2019;134(6):1234–1244
  • Kadir RA, Sabin CA, Pollard D, et al. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia. 1998;4(6):836–841
  • van Hoorn ES, Houwing ME, Al Arashi W, et al. Patient-reported outcomes in autosomal inherited bleeding disorders: a systematic literature review. Haemophilia. 2022;28(2):197–214
  • McGrath M, Quint EH, Weyand AC. Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting. Am J Hematol. 2021;96(4):E105–E8.
  • Weyand AC, Fitzgerald KD, McGrath M, et al. Depression in female adolescents with heavy menstrual bleeding. J Pediatr. 2022;240:171–176.
  • Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6(6):643–648
  • Hews-Girard JC, Galica J, Goldie C, et al. Determining the incidence of postpartum haemorrhage among Ontario women with and without inherited bleeding disorders: a population-based cohort study. Haemophilia. 2022;28(5):832–841
  • James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost. 2007;5(6):1165–1169.
  • Malec LM, Moore CG, Yabes J, et al. Postpartum haemorrhage in women with von Willebrand disease: an observational study of the Pennsylvania Health Care Cost Containment Council (PHC4) database. Haemophilia. 2015;21(5):e442–5
  • Miller CH, Philipp CS, Stein SF, et al. The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia. 2011;17(1):e223–9
  • United Kingdom Haemophilia Centre doctors’ organisation and national haemophilia database. UKHCDO Annual Report 2020 & Bleeding Disorder Statistics for 2020/2021. Manchester, Unite Kingdom; 2021 [cited 2022 Jul 25]. Available from: http://www.ukhcdo.org/wp-content/uploads/2021/12/2021-UKHCDO-Annual-Report-2020-21-Data.pdf
  • Renault NK, Howell RE, Robinson KS, et al. Qualitative assessment of the emotional and behavioural responses of haemophilia A carriers to negative experiences in their medical care. Haemophilia. 2011;17(2):237–245.
  • van Galen KPM, d’Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost. 2021;19(8):1883–1887
  • Weyand AC, Sidonio RF Jr., Sholzberg M. Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues. Haemophilia. 2022;28(Suppl 4):18–25.
  • Chaudhury A, Sidonio R Jr., Jain N, et al. Women and girls with haemophilia and bleeding tendencies: outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. Haemophilia. 2021;27(2):293–304
  • d’Oiron R, O’Brien S, James AH, et al. Women and girls with haemophilia: lessons learned. Haemophilia. 2021;27 Suppl 3:75–81.
  • Gilbert L, Rollins L, Hilmes M, et al. Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes. Haemophilia. 2014;20(6):e426–9
  • Kirtava A, Drews C, Lally C, et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia. 2003;9(3):292–297
  • Olsson A, Hellgren M, Berntorp E, et al. Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B. Blood Coagul Fibrinolysis. 2014;25(5):471–475
  • Puetz J, Cheng D. Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset. Haemophilia. 2021;27(6):1045–1050.
  • Sidonio RF, Mili FD, Li T, et al. Females with FVIII and FIX deficiency have reduced joint range of motion. Am J Hematol. 2014;89(8):831–836
  • Arnegard ME, Whitten LA, Hunter C, et al. Sex as a biological variable: a 5-year progress report and call to action. J Womens Health (Larchmt). 2020;29(6):858–864.
  • Dasarathy J, Labrador H. Bone health in women. Prim Care. 2018;45(4):643–657.
  • Knol HM, Kemperman RF, Kluin-Nelemans HC, et al. Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost. 2012;107(1):22–29
  • Miller CH, Dilley AB, Drews C, et al. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost. 2002;87(6):1082–1083
  • Dupuis M, Severin S, Noirrit-Esclassan E, et al. Effects of Estrogens on Platelets and Megakaryocytes. Int J Mol Sci. 2019;20(12):12
  • James AH, Ragni MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology?. Hematology Am Soc Hematol Educ Program. 2006;2006(1):474–485.
  • Oral Contraceptive Hemostasis Study Group . The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception. 2003;67(3):173–185.
  • Connors JM, Middeldorp S. Transgender patients and the role of the coagulation clinician. J Thromb Haemost. 2019;17(11):1790–1797.
  • Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015;70(Suppl 1):78–86.
  • Critchley HOD, Babayev E, Bulun SE, et al. Menstruation: science and society. Am J Obstet Gynecol. 2020;223(5):624–664
  • Zia A, Lau M, Journeycake J, et al. Developing a multidisciplinary young women’s blood disorders program: a single-centre approach with guidance for other centres. Haemophilia. 2016;22(2):199–207
  • Sidonio RF Jr., Zia A, Fallaize D. Potential undiagnosed VWD or other mucocutaneous bleeding disorder cases estimated from private medical insurance claims. J Blood Med. 2020;11:1–11.
  • Arya S, Wilton P, Page D, et al. Healthcare provider perspectives on inequities in access to care for patients with inherited bleeding disorders. PLoS One. 2020;15(2):e0229099
  • Weyand AC, James PD. Sexism in the management of bleeding disorders. Res Pract Thromb Haemost. 2021;5(1):51–54.
  • Lopez K, Norris K, Hardy M, et al. Defining the impact of social drivers on health outcomes for people with inherited bleeding disorders. J Clin Med. 2022;11:15.
  • Arya S, Wilton P, Page D, et al. “Everything was blood when it comes to me”: understanding the lived experiences of women with inherited bleeding disorders. J Thromb Haemost. 2020;18(12):3211–3221
  • James AH. Von Willebrand: an underdiagnosed disorder 2017 [cited 2022 May 3]. Available from: https://www.contemporaryobgyn.net/view/von-willebrand-underdiagnosed-disorde.
  • Arya S, Wilton P, Page D, et al. “They don’t really take my bleeds seriously”: barriers to care for women with inherited bleeding disorders. J Thromb Haemost. 2021;19(6):1506–1514
  • Khair K, Holland M, Pollard D. The experience of girls and young women with inherited bleeding disorders. Haemophilia. 2013;19(5):e276–81.
  • Vázquez E, Kim M, Santaella ME. Lived experience experts: a name created by us for us, Expert Rev Hematol, 2023;16(S1):7–11. DOI: 10.1080/17474086.2023.2178410.
  • Mirin AA. Gender disparity in the funding of diseases by the U.S. national institutes of health. J Womens Health (Larchmt). 2021;30(7):956–963.
  • Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020;26(1):17–24
  • Valentino LA, Witkop ML, Santaella ME, et al. The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary. Expert Rev Hematol. 2023;16(S1):127–132. DOI: 10.1080/17474086.2023.2181782.
  • Valentino LA, Witkop ML, Santaella ME, et al. Building the blueprint: formulating a community-generated national plan for future research in inherited bleeding disorders. Haemophilia. 2022;28(5):760–768
  • Valentino LA, Witkop ML, Santaella ME, et al. The National Hemophilia Foundation's State of the Science Research Summit initiative: the foundation of an inherited bleeding disorders national research blueprint. Expert Rev Hematol. 2023;16(S1):1–5. DOI: 10.1080/17474086.2023.2178412.
  • Lillicrap D, Fijnvandraat K, Young G, et al. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020;13(4):313–321.
  • Sabatino DE, Pipe SW, Nugent DJ, et al. Origins and organization of the NHLBI state of the science workshop: generating a national blueprint for future research on factor VIII inhibitors. Haemophilia. 2019;25(4):575–580
  • Tran DQ, Benson CC, Boice JA, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia. Expert Rev Hematol. 2023;16(S1):19–37. DOI: 10.1080/17474086.2023.2171981.
  • Sidonio RF Jr., Bryant PC, Di Paola J, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders. Expert Rev Hematol. 2023;16(S1):39–54. DOI: 10.1080/17474086.2023.2171983.
  • Byams VR, Baker JR, Bailey C, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science. Expert Rev Hematol. 2023;16(S1):87–106. DOI: 10.1080/17474086.2023.2183836.
  • Byams VR, Miller CH, Bethea FM, et al. Bleeding Disorders in Women and Girls: state of the Science and CDC Collaborative Programs. J Womens Health (Larchmt). 2022;31(3):301–309
  • Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004;10(2):158–161
  • Srivaths LV, Zhang QC, Byams VR, et al. Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding. Haemophilia. 2018;24(1):63–69
  • Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. Haemophilia. 1999;5(5):313–317.
  • American Academy of Pediatrics Committee on Adolescence and American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Diaz A, Laufer MR, Breech LL. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 2006;118(5):2245–2250.
  • Byams VR, Anderson BL, Grant AM, et al. Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists. Am J Obstet Gynecol. 2012;207(4):269 e1–5
  • Screening and management of bleeding disorders in adolescents with heavy menstrual bleeding: ACOG COMMITTEE OPINION, Number 785. Obstet Gynecol. 2019;134(3):e71–e83
  • James P. About Let’s Talk Period [cited Oct 4, 2022]. Available from: https://letstalkperiod.ca/about/.
  • IWK Health. WeThrive: period tracking for quality of life [cited 2022 Oct 4]. Available from: https://youriwk.com/2022/06/02/we-thrive-period-tracking-for-quality-of-life/.
  • Brown MC, White MH, Friedberg R, et al. Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease. Res Pract Thromb Haemost. 2021;5(4):e12513
  • Indiana Hemophilia & Thrombosis Center. Partners in bleeding disorders education [cited 2022 Sept 17]. Available from: https://www.partnersprn.org/.
  • Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505(7485):612–613.
  • National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management [cited 2022 May 4]. Available from: https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-pdf-1837701412549.
  • Magnay JL, O’Brien S, Gerlinger C, et al. A systematic review of methods to measure menstrual blood loss. BMC Womens Health. 2018;18(1):142.
  • U.S. Food and Drug Administration. Prescribing Information. Mirena (levonorgestrel-releasing intrauterine system) [cited 2022 May 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021225s042lbl.pdf.
  • U.S. Food and Drug Administration. Prescribing Information. Natazia (estradiol valerate and estradiol valerate/dienogest) tablets, for oral use [cited 2022 May 4]. Available from: https://labeling.bayerhealthcare.com/html/products/pi/natazia_pi.pdf.
  • Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964;16:244–248.
  • Hallberg L, Hogdahl AM, Nilsson L, et al. Menstrual blood loss–a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320–351
  • Magnay JL, O’Brien S, Gerlinger C, et al. Pictorial methods to assess heavy menstrual bleeding in research and clinical practice: a systematic literature review. BMC Womens Health. 2020;20(1):24.
  • Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception. 2012;85(3):246–252.
  • European Medicines Agency. Summary of product characteristics. Esmya 5mg tablets, INN-Ulipristal [cited 2022 May 4]. Available from: https://www.ema.europa.eu/en/documents/product-information/esmya-epar-product-information_en.pdf.
  • Hoaglin DC, Filonenko A, Glickman ME, et al. Use of mixed-treatment-comparison methods in estimating efficacy of treatments for heavy menstrual bleeding. Eur J Med Res. 2013;18:17.
  • Nugent D, Acharya SS, Baumann KJ, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders. Expert Rev Hematol. 2023;16(S1):55–70. DOI: 10.1080/17474086.2023.2175661.
  • Ragni MV, Young G, Batsuli G, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: Facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023;16(S1):107–127. DOI: 10.1080/17474086.2023.2181781.
  • Johns Hopkins Center for Communication Programs. Technical consultation on contraceptive-induced menstrual changes: new perspectives on research that can improve women’s lives globally [cited 2022 Jun 12]. Available from: https://knowledgesuccess.org/2021/01/20/technical-consultation-on-contraceptive-induced-menstrual-changes/.
  • Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939